SCHEDULE 13D/A 0000921895-23-002457 0000918923 XXXXXXXX LIVE 3 Common Shares, no par value 01/28/2026 true 0001808158 760273102 Repare Therapeutics Inc.

7171 FREDERICK BANTING SUITE 270, BUILDING 2 SAINT-LAURENT A8 H4S 1Z9

JAMES KRATKY 415-525-8830 BVF PARTNERS L.P. 44 Montgomery St., 40th Floor San Francisco CA 94104 0000918923 N BIOTECHNOLOGY VALUE FUND L P a N DE 0.00 0.00 0.00 0.00 0.00 N 0 PN 0001803805 N BVF I GP LLC a N DE 0.00 0.00 0.00 0.00 0.00 N 0 OO 0001102444 N BIOTECHNOLOGY VALUE FUND II LP a N DE 0.00 0.00 0.00 0.00 0.00 N 0 PN 0001803806 N BVF II GP LLC a N DE 0.00 0.00 0.00 0.00 0.00 N 0 OO 0001660683 N Biotechnology Value Trading Fund OS LP a N E9 0.00 0.00 0.00 0.00 0.00 N 0 PN 0001660684 N BVF Partners OS Ltd. a N E9 0.00 0.00 0.00 0.00 0.00 N 0 CO 0001803809 N BVF GP HOLDINGS LLC a N DE 0.00 0.00 0.00 0.00 0.00 N 0 OO 0001055947 N BVF PARTNERS L P/IL a N DE 0.00 0.00 0.00 0.00 0.00 N 0 IA PN 0001056807 N BVF INC/IL a N DE 0.00 0.00 0.00 0.00 0.00 N 0 CO 0001233840 N LAMPERT MARK N a N X1 0.00 0.00 0.00 0.00 0.00 N 0 IN Common Shares, no par value Repare Therapeutics Inc. 7171 FREDERICK BANTING SUITE 270, BUILDING 2 SAINT-LAURENT A8 H4S 1Z9 Item 3 is hereby amended and restated to read as follows: As described in Items 4 and 5 below, the Reporting Persons no longer beneficially own any Shares. Item 4 is hereby amended to add the following: Effective January 28, 2026, the Issuer was acquired by Xeno Acquisition Corp. ("Purchaser"), a wholly-owned subsidiary of XenoTherapeutics, Inc. ("Xeno"), pursuant to an Arrangement Agreement, dated as of November 14, 2025 (the "Agreement"), under the Business Corporations Act (Quebec), by and among the Issuer, Xeno, Purchaser, and solely for limited purposes, XOMA Royalty Corporation, pursuant to which Purchaser agreed to acquire all of the issued and outstanding Shares of the Issuer. Pursuant to the Agreement, among other things, the Purchaser acquired all of the issued and outstanding Shares of the Issuer in exchange for: (i) $2.20 in cash per Share and (ii) one contingent value right per Share for potential cash payments. Accordingly, the Reporting Persons ceased to beneficially own any securities of the Issuer. Item 5(a) is hereby amended and restated to read as follows: As described in Item 4 above, the Reporting Persons no longer beneficially own any Shares. Item 5(c) is hereby amended and restated to read as follows: Except as set forth in Item 4 above, the Reporting Persons have not entered into any transactions in the securities of the Issuer during the past 60 days. Item 5(e) is hereby amended and restated to read as follows: As of January 28, 2026, the Reporting Persons ceased to be the beneficial owners of more than 5% of the outstanding Shares. BIOTECHNOLOGY VALUE FUND L P /s/ Mark N. Lampert 01/30/2026 BVF I GP LLC /s/ Mark N. Lampert 01/30/2026 BIOTECHNOLOGY VALUE FUND II LP /s/ Mark N. Lampert 01/30/2026 BVF II GP LLC /s/ Mark N. Lampert 01/30/2026 Biotechnology Value Trading Fund OS LP /s/ Mark N. Lampert 01/30/2026 BVF Partners OS Ltd. /s/ Mark N. Lampert 01/30/2026 BVF GP HOLDINGS LLC /s/ Mark N. Lampert 01/30/2026 BVF PARTNERS L P/IL /s/ Mark N. Lampert 01/30/2026 BVF INC/IL /s/ Mark N. Lampert 01/30/2026 LAMPERT MARK N /s/ Mark N. Lampert 01/30/2026